Anti-HIV-1 activity of GRFT and its mutant variants in different cell systems.

aEC50 required to inhibit virus-induced cytopathicity in CEM (HIV-1 IIIB) cell cultures by 50%. bEC50 required to inhibit virus (HIV-1 NL4.3)-induced cytopathicity in C8166 cell cultures by 50%. c50%-Effective concentration or compound concentration required to inhibit syncytia formation between persistently HIV-1(IIIB)-infected HuT-78/HIV-1 cells and uninfected CD4+ T-lymphocyte Sup T1 cells by 50%. d50%-Effective concentration or compound concentration required to inhibit syncytia formation between persistently HIV-1(IIIB)-infected HuT-78/HIV-1 cells and uninfected CD4+ T-lymphocyte C8166 cells by 50%. The data from which the EC50's were derived are shown in Figures S1, S2, S3, S4, S5 and are the mean of at least 2 to 3 independent experiments.